Results 31 to 40 of about 11,837 (160)
International Journal of Infectious Diseases, 2017 Objective: This study compared the activity of ceftolozane–tazobactam and ceftazidime–avibactam against 120 bacterial strains, including extended-spectrum beta-lactamase (ESBL) producers, carbapenem-resistant Enterobacteriaceae (CRE), and Pseudomonas ...
Adnan Alatoom +9 more
doaj +1 more source
Frontiers in Microbiology, 2022 Ceftazidime-avibactam is one of the last resort antimicrobial agents for the treatment of carbapenem-resistant, Gram-negative bacteria. Metallo-β-lactamase-producing bacteria are considered to be ceftazidime-avibactam resistant. Here, we evaluated a semi-
Michaela Simon +16 more
doaj +1 more source
mSphere, 2020 Ceftazidime-avibactam is a potent antibiotic combination against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae. Here, we describe a unique ceftazidime-avibactam-resistant and carbapenem-susceptible K.
Siqiang Niu +9 more
doaj +3 more sources
Brazilian Journal of Infectious Diseases, 2021 The Antimicrobial Testing Leadership and Surveillance (ATLAS) global surveillance program collected clinical isolates of Enterobacterales (n = 8416) and Pseudomonas aeruginosa (n = 2521) from 41 medical centers in 10 Latin American countries from 2017 to
James A. Karlowsky +8 more
doaj +1 more source
Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature
Antibiotics, 2023 Bone and joint infections (BJIs) caused by multidrug-resistant gram-negative bacteria are becoming a concern due to limited therapeutic options. Although not approved for these indications, an ever-growing amount of evidence supports the efficacy and ...
Alessandro Mancuso +5 more
doaj +1 more source
Microbiology Spectrum, 2022 We describe an outbreak of Klebsiella pneumoniae sequence type 11 (ST11) producing KPC variants resistant to ceftazidime-avibactam. Six patients hospitalized in the intensive care unit (mostly due to critical COVID pneumonia) presented infection or ...
Federico Nicola +9 more
doaj +1 more source
Clinical Infectious Diseases, 2022 BACKGROUND Patients with bacteremia due to carbapenem-resistant Enterobacterales (CRE) experience delays until appropriate therapy and high mortality rates.
M. Satlin +21 more
semanticscholar +1 more source
Ceftazidime/Avibactam: Who Says You Can’t Teach an Old Drug New Tricks?
Journal of Pharmacy & Pharmaceutical Sciences, 2016 Purpose: Gram-negative resistance continues to rise with treatment options becoming more limited. Ceftazidime/avibactam was recently approved in the United States and Europe, which combines an established third-generation cephalosporin with a new, unique,
Katie E. Barber +2 more
doaj +1 more source
Potent monoclonal antibodies against multidrug‐resistant hypervirulent Klebsiella pneumoniae
Interdisciplinary Medicine, EarlyView.A novel immunization strategy using a low‐virulence, multidrug‐resistant strain yields synergistic monoclonal antibodies against hypervirulent Klebsiella pneumoniae. These antibodies provide cross‐serotype protection through a dual‐mechanism of pathogen clearance and immunomodulation, offering a promising non‐antibiotic therapeutic for resistant ...
Yushan Jiang +10 more
wiley +1 more source
Journal of Global Antimicrobial Resistance, 2020 Objectives: The aim of this study was to report on in vitro tests of antibacterial activity of ceftazidime/avibactam in combination against planktonic or biofilm KPC carbapenemase-producing Klebsiella pneumoniae (KPC-Kp), the rate of KPC-Kp blood ...
Chiara Papalini +6 more
doaj +1 more source